02591.HK
Guangzhou Innogen Pharmaceutl Grp Co Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 3.85
+0.26%Margins
Gross margin
76.0%
EBITDA margin
-211.0%
EBIT margin
-219.5%
Net margin
-218.0%
FCF margin
-239.9%
-34.9%
Return on equity
-25.3%
Return on assets
-30.3%
Return on invested capital
0.11x
Asset turnover
-HKD 401.9M
Cash from operations
HKD 2.70
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026